Aragen operationalises first phase of biologics manufacturing facility in Bengaluru
India, March 28 -- Aragen,a leading Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics, has operationalised the first phase of its biologics manufacturing facility in Bengaluru, through its 100% subsidiary, Aragen Biologics.
The facility is being set up at an investment of $30 million. It has also executed its first small-scale manufacturing project for a US-based organisation for manufacturing a novel anticancer monoclonal antibody (mAb). The non-GMP facility can undertake batch sizes upto 50 Ltrs and includes process development and analytical labs to support the manufacturing activities.
Manni Kantipudi, CEO, Aragen Life Sciences and Director of Aragen Biologicssaid,"Once the facili...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.